Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  sirolimus
Find trials that include:  Any drugs shown
Results 1-25 of 40 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NA_00039823 / CIR00009182, NCT01203722
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: Under 30
Trial IDs: 10-491-B, NCI-2016-00591, 44574, NCT01265030
Donor Peripheral Blood Stem Cell transplantation Followed by Lenalidomide and Sirolimus in Treating Patients With High-Risk Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 70
Trial IDs: IUCRO-0307, NCI-2011-00266, 1012-24, 1105005328, NCT01303965
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MC1125, NCI-2012-00518, 11-001987, NCT01737502
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients with Bladder Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8027, NCI-2013-01614, NCT01938573
Palifermin in Preventing Graft-versus-Host Disease in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Prevention
Age: 18 to 70
Trial IDs: 15-C-0067, NCI-2015-00084, P131448, NCT02356159
Sirolimus, Docetaxel, and Carboplatin in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9388, NCI-2015-01478, NCT02565901
PLX3397 and Sirolimus in Treating Patients with Sarcoma or Malignant Peripheral Nerve Sheath Tumors That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO6059, NCI-2015-01768, NCT02584647
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients with Hematologic Malignancies Undergoing HSCT
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Age: 3 to 30
Trial IDs: PEDSBMT295, NCI-2016-00387, NCT02728700
Donor Stem Cell Transplant and T-Cell Infusion with or without Low-Intensity Preparative Chemotherapy Using Sirolimus in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: 04-C-0055, NCI-2013-01407, 040055, 351967, NCI-2013-01404, NCT00077480, NCI-04-C-0055, NCT00074490
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Fludarabine Phosphate, Melphalan, and Total-Body Irradiation before Donor Double Umbilical Cord Blood Transplant in Treating Patients with Hematological Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 11-085, NCI-2012-00147, NCT01408563
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Donor Stem Cell Transplant in Treating Patients with GATA2 Mutations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 70
Trial IDs: 13-C-0132, NCI-2013-01561, 130132, P131226, NCT01861106
Sirolimus and Azacitidine in Treating Patients with High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That Is Relapsed or Refractory or Not Eligible for Intensive Chemotherapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12D.587, NCI-2013-01004, 2012-50, NCT01869114
Clofarabine and Melphalan before Donor Stem Cell Transplant in Treating Patients with Myelodysplasia or Acute Leukemia in Remission
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 13130, NCI-2013-01193, 107819, 119416, 122471, NCT01885689
Bortezomib in Preventing Graft-versus-Host Disease after Reduced-Intensity Donor Stem Cell Transplant in Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: 12-404, NCI-2013-00623, X05412, NCT01754389
Reduced Intensity Conditioning and Donor Bone Marrow Transplant in Treating Patients With Sickle Cell Disease and Hemoglobinopathies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 70
Trial IDs: VICC BMT 12108, NCI-2013-00984, 121477, NCT01850108
In Vivo Treg Expansion and Graft-versus-Host Disease Prophylaxis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention, Treatment
Age: 18 and over
Trial IDs: MCC # 17578, NCI-2014-00755, NCT01927120
Nonmyeloablative Donor Stem Cell Transplant in Treating Patients with Congenital Anemias including Sickle Cell Disease and Thalassemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 55
Trial IDs: 012013-015, NCI-2014-02134, NCT02038478
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients with High-Risk Acute Myeloid Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15D.377, NCI-2015-01507, 2013-087, CCRRC 2013-087, JT#5530, JT#5530/CCRRC 2013-087, NCT02583893
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: AFLACST1502, NCI-2015-01637, IRB00082488, NCT02574728
Pentostatin and Cyclophosphamide, with or without Busulfan before Donor Blood or Bone Marrow Transplant in Treating Patients with Primary Immunodeficiencies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 75
Trial IDs: 16-C-0003, NCI-2015-01788, 160003, P152242, NCT02579967
Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: MCC-18374, NCI-2016-00054, Novartis CLBH589BUS100T, NCT02588339
Start Over